12:52 PM
 | 
Apr 20, 2018
 |  BC Extra  |  Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >